October 26, 2026

MEDIPAL HOLDINGS CORPORATION
Representative: Kuniaki Imagawa, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Toshiyuki Ikeuchi,
Executive Officer, Head of Corporate Communications Department,
Corporate Planning Division
Tel: +81-3-3517-5171

Notice Regarding Shareholder's Petition for Permission to Convene an Extraordinary General Meeting of Shareholders

As announced in the "Notice Regarding Shareholder's Demand to Convene an Extraordinary General Meeting of Shareholders" dated September 2, 2026, MEDIPAL HOLDINGS CORPORATION (the "Company") received a document from a shareholder of the Company, requesting the convocation of an extraordinary general meeting of shareholders. The Company hereby announces that today it received from the Tokyo District Court a written petition filed by such shareholder for permission to convene a general meeting of shareholders of the Company (the "Petition").

1. Overview of the Shareholder Filing the Petition
The Northern Trust Company AVFC Re: Silchester International Investors International Value Equity Trust
The requesting shareholder has continuously held 3% or more of the total voting rights of all shareholders of the Company for six months or longer.

2. Contents of the Petition
The Petition seeks a court decision granting permission to convene a general meeting of shareholders with the following matters to be the purposes of the shareholders' meeting:
Proposal No. 1: Dismissal of Director Shuichi Watanabe
Proposal No. 2: Partial Amendments to the Articles of Incorporation
Proposal No. 3: Dividend of Surplus (Special Dividend)
Proposal No. 4: Buyback of Own Shares

3. Future Outlook

If any matter requiring disclosure arises in the future, the Company will promptly announce the same.

# # #

The English version of this document is a translation of the Japanese original and is provided for informational purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. If there are any inconsistencies or conflicts between the English version and the Japanese original, the Japanese original shall prevail.